<DOC>
	<DOCNO>NCT02398448</DOCNO>
	<brief_summary>The purpose study determine whether define limited change vitro dissolution impact vivo pharmacokinetics ( PK ) relative bioavailability allopurinol active metabolite oxypurinol .</brief_summary>
	<brief_title>IVIVR Assessing PK Parameters Used Establish Bioequivalence</brief_title>
	<detailed_description>In study , single oral dose Zyloprim® ( 300 mg tablet ) 3 separate single oral dos 300 mg allopurinol test formulation ( Regimens B , C D ) administer sequentially subject separate occasion . Following administration Regimens B C , period interim analysis PK data review determine formulation within process design space provide desired vitro dissolution variant dose subsequent study period .</detailed_description>
	<mesh_term>Allopurinol</mesh_term>
	<criteria>Body mass index 18.0 35.0 kg/m2 inclusive , outside range , consider clinically significant Investigator . Must exceed 40.0 kg/m2 . Must agree use adequate method contraception Subjects test positive HLAB*5801 allele . Subjects receive last dose IMP ( treatment medical device ) within previous 3 month prior Day 1 currently participate another study IMP ( medical device ) . History drug alcohol abuse past 2 year . Regular alcohol consumption male &gt; 21 unit per week ( 1 unit = ½ pint beer , 25 mL 40 % spirit 125 mL glass wine ) . Current smoker smoke within last 12 month prior Screening . A breath carbon monoxide read great 10 ppm Screening . Subjects suitable vein multiple venepunctures/cannulation assess Investigator Screening . Clinically significant screen laboratory parameter ( biochemistry [ AST ALT &gt; 1.5 × ULN ] , hematology urinalysis ) judge Investigator ( laboratory parameter list Appendix 1 ) . Positive drug abuse test result Screening Admission ( drug abuse test list Appendix 1 ) . Positive hepatitis B surface antigen ( HBsAg ) , hepatitis C virus antibody ( HCV Ab ) human immunodeficiency virus ( HIV ) result . Subjects rare hereditary problem galactose intolerance , Lapp lactase deficiency glucosegalactose malabsorption . History cardiovascular , renal , hepatic , chronic respiratory gastrointestinal disease judge Investigator . Evidence renal impairment Screening , indicate estimate creatinine clearance &lt; 90 mL/min use CockcroftGault equation . Serious adverse reaction serious hypersensitivity drug formulation excipients . Presence history clinically significant allergy require treatment , judge Investigator . Hayfever allow unless active . Donation loss great 400 mL blood within previous 3 month prior Screening . Subjects take , take , prescribed overthecounter drug ( 4 g per day paracetamol ) herbal remedy 14 day IMP administration ( See Section 11.4 ) .</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>December 2015</verification_date>
</DOC>